Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00358358
Status:
COMPLETED
Last Update Posted:
2017-01-20
First Post:
2006-07-27
Brief Title:
Chronic Obstructive Pulmonary Disease Endpoints Study
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Study of Treatments With Salmeterol Fluticasone Propionate and Their Combination to Evaluate Novel Endpoints in Patients With Chronic Obstructive Pulmonary Disease
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will last for approximately 14 weeks and will involve 5 visits The study is being carried out to look at different ways of measuring the effect of drug treatment on COPD COPD is a respiratory disease which can affect your breathing and daily life Symptoms of COPD can include breathlessness cough and wheeze COPD varies enormously from patient to patient The effects of drug treatment are usually measured by conducting lung function tests breathing tests using a machine called a spirometer but this does not always provide a complete picture of how well your COPD is responding In this study we therefore want to look at new and more sensitive ways of measuring COPD The results of this research will help in the assessment of new drugs for COPD in the future
Detailed Description:
Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease COPD in a Randomized Double-Blind Placebo-Controlled Study of Treatment with Fluticasone PropionateSalmeterol 50050mcg combination FSC 50050 and its individual components Fluticasone Propionate 500mcg FP500 and Salmeterol 50mcg SAL 50
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None